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Background {#sec005}
==========

Breast cancer is a life-threatening cancer among women and is the sixth most common cause of death among women in China \[[@pone.0232174.ref001]\]. The American Cancer Society estimated that there were 252,710 new breast cancer cases in the United States in 2017, and approximately 40,610 deaths in women occurred due to breast cancer \[[@pone.0232174.ref002]\]. Although numerous environmental factors are well known to cause breast cancer, genetic factors have been confirmed to play a crucial role in the progression of the disease \[[@pone.0232174.ref003], [@pone.0232174.ref004]\].

A growing number of genome-wide association studies have found that variants in genes can significantly affect the susceptibility to breast cancer \[[@pone.0232174.ref005], [@pone.0232174.ref006]\]. However, currently identified single nucleotide polymorphisms (SNPs) can only shed partial insight into the inherited causes of breast cancer, and the precise mechanisms underlying breast cancer remain unclear. Therefore, it is valuable to explore novel SNP loci for assessing the risk of breast cancer. The human interleukin-10 gene (*IL-10*) is located on chromosome 1q32.1 and contains four introns and five exons \[[@pone.0232174.ref007]\]. IL-10 is a highly pleiotropic cytokine that is produced by various cells. Studies have shown that IL-10 plays an important role in the initiation and development of breast cancer \[[@pone.0232174.ref008]\]. Expression of IL-10 is higher in breast cancer patients than in healthy persons \[[@pone.0232174.ref009], [@pone.0232174.ref010]\]. Ahmad et al. \[[@pone.0232174.ref011]\] demonstrated that IL-10 has an inhibitory effect on the migration of breast cancer cell lines, and this study also found that breast cancer patients with higher IL-10 levels show better disease-free survival and breast cancer-specific survival in the early stages of invasive breast cancer. Thus, IL-10 has been suggested as a potential prognostic marker for breast cancer \[[@pone.0232174.ref012]\], and there may be a genetic correlation between *IL-10* and breast cancer susceptibility. Several studies \[[@pone.0232174.ref013], [@pone.0232174.ref014]\] have investigated the relationships between *IL-10* polymorphisms and breast cancer risk, but have not completely clarified.

Here, we genotyped six SNPs (rs1554286, rs1518111, rs3021094, rs3790622, rs3024490, rs1800871) of IL-10 genes in a case-control study to explore the association between polymorphisms of *IL-10* and the risk of breast cancer in Northwest Chinese Han women. Our data shed new light on the association between IL-10 SNPs and breast cancer susceptibility in Shaanxi Han women in China.

Methods {#sec006}
=======

Ethics approval and consent to participate {#sec007}
------------------------------------------

All participants were informed of the procedures and purpose of this study. Signed informed consent documents were obtained from both patients and healthy individuals. Study protocols were approved by the Ethical Committee of the First Affiliated Hospital of Xi'an Jiaotong University, and complied with the ethical standards of the Ethical Committee and World Medical Association Declaration of Helsinki. All subsequent research analyses were carried out in accordance with approved guidelines and regulations.

Study participants {#sec008}
------------------

The case and control study included 530 breast cancer patients and 628 healthy controls, who were recruited from September 2016 to June 2019 at the First Affiliated Hospital of Xi'an Jiaotong University. The case groups confirmed breast cancer through histological examination, and all cases were diagnosed with a new breast cancer event. Patients diagnosed with other types of cancer and / or receiving hormone therapy, radiotherapy or chemotherapy were excluded. The control groups were healthy women who had undergone an annual health assessment and were recruited from a health checkup center affiliated to our institution. These women did not have any positive signs of cancer and had no history of malignant family history. The case and control groups were all Chinese Han women living in Shaanxi Province, and there was no blood relationship between them.

SNP selection and genotyping {#sec009}
----------------------------

Total genomic DNA was isolated using a GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GlodMag Co. Ltd., Xi'an, China) from peripheral blood, according to the manufacturer's protocol. The Agena Bioscience Assay Design Suite V2.0 software (<https://agenacx.com/online-tools/>) was used to design the extended primer. SNPs were genotyped using the MassARRAY Nanodispenser (Agena Bioscience, San Diego, CA, USA) and MassARRAY iPLEX platform (Agena Bioscience, San Diego, CA, USA), according to the standard protocol recommended by the manufacturer.

According to the standard protocol recommended by the manufacturer, two laboratory personnel used the MassARRAY Nanodispenser (Agena Bioscience, San Diego, CA, USA) and MassARRAY iPLEX platform (Agena Bioscience, San Diego, CA, USA) to genotype SNPs in a double-blind manner. About 10% of the samples were randomly selected for repeated genotyping to confirm the results, and the reproducibility was 100%. The Agena Bioscience TYPER software (version 4.0) was used for data management and analyses.

In this study, six SNPs (rs1554286, rs1518111, rs3021094, rs3790622, rs3024490, rs1800871) of *IL-10* were selected from the DbSNP (<http://www.hapmap.org/index.html.en>) and SNP Consortium (<http://snp.cshl.org/>) databases based on the following criteria. We took allele frequency into consideration during genotyping. The lower frequency alleles were coded as minor alleles. All SNPs were selected at a minor allele frequency \>5% in the 1,000 genome project (<http://www.internationalgenome.org/>). Chinese Han Beijing population, and the genotype distribution of SNPs in the control group was in accordance with Hardy-weinberg equilibrium (HWE) (*p*\> 0.05). The genotyping of Agena MassARRAY RS1000 for these SNPs exceeded 95.0%.

Statistical analysis {#sec010}
--------------------

Microsoft Excel and SPSS 18.0 statistical package (SPSS, Chicago, IL, USA) were used for statistical analyses. All *p*-values were based on two-sided tests, and *p* ≤ 0.05 was considered as the threshold of statistical significance. Welch's t-test was used to compare ages between cases and controls. The validation of each SNP frequency in control subjects was tested for departure from the Hardy-Weinberg Equilibrium (HWE) using an exact test, and the difference in allele frequency distribution among cases and controls was assessed using Pearson's chi-square test. Subsequently, unconditional logistic regression analysis was used to evaluate breast cancer susceptibility under four genotype models (co-dominant, dominant, recessive, and additive model). The SNPStats software platform (<https://www.snpstats.net/start.htm>) and Haploview software package (version 4.2) \[[@pone.0232174.ref015]\] were used to perform the linkage disequilibrium (LD) and analyze the association between haplotypes and the risk of breast cancer. The effects of *IL-10* polymorphisms on the risk of breast cancer were expressed as odds ratios (ORs) and 95% confidence intervals (CIs) \[[@pone.0232174.ref016]\].

Functional annotation {#sec011}
---------------------

*In silico* analysis of breast cancer-associated SNPs on gene expression was assessed using the genotype-tissue expression (GTEx) database of quantitative trait loci (eQTL) variants. This is used to determine the biological effects of genetic variants (<http://www.gtexportal.org>). Mapping of eQTLs provides a powerful approach to uncover the genetic factors underlying altered gene expression \[[@pone.0232174.ref017]\].

Regulome DB (<http://www.regulomedb.org/>) was used to determine the effect of *IL-10* SNPs on allele-specific transcription factor binding. Regulome DB utilizes chromatin immunoprecipitation-sequencing data and chromatin state information across many cell types, as well as eQTL information, for the functional annotation of variants. The variants are scored based on predicted potential effects caused by the variant residing in a functionally important region of the genome. The lower the score the higher impact on protein binding and expression of the target gene.

In addition, HaploReg (<http://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>) has been used to explore annotations of the noncoding genome at variants on haplotype blocks \[[@pone.0232174.ref018]\]. We used HaploReg (version 4.1) to assess the rs3024490- and rs1800871-tagged SNPs using LD information from the 1000 Genomes Project with r^2^ ≥ 0.8.

Results {#sec012}
=======

Participant characteristics {#sec013}
---------------------------

A total of 530 breast cancer patients and 628 healthy individuals were enrolled. Demographics and clinical characteristics are shown in [Table 1](#pone.0232174.t001){ref-type="table"}. The mean ages of cases and controls were 50.69 and 51.04 years, respectively. Welch's t-test revealed significant differences in age between cases and controls (*p* = 0.001).

10.1371/journal.pone.0232174.t001

###### Characteristics of cases and controls.

![](pone.0232174.t001){#pone.0232174.t001g}

  Variables                               Cases (N = 530)   Controls (N = 628)   *p*-value
  ---------------------- ---------------- ----------------- -------------------- ---------------------------------------------
  Age, years (mean±SD)                    50.69 ± 11.74     51.04 ± 9.64         0.001[^a^](#t001fn002){ref-type="table-fn"}
  Age, years             \> 50            276 (52.08%)      336 (53.50%)         
                         ≤ 50             254 (47.92%)      292 (46.50%)         
  Tumor classification   \< 2mm           232 (43.77%)                           
                         ≥ 2mm            298 (56.23%)                           
  ER status              Negative         220 (41.51%)                           
                         Positive         310 (58.49%)                           
  PR status              Negative         278 (52.45%)                           
                         Positive         252 (47.55%)                           
  HER2 status            Negative         208 (39.25%)                           
                         Positive         322 (60.75%)                           
  Menopause Status       Pre-menopause    216 (40.75%)                           
                         Post-menopause   314 (59.25%)                           

SD, standard deviation; ER: estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

^a^*p*-value was calculated using Welch's t test.

Association between IL-10 polymorphisms and breast cancer risk {#sec014}
--------------------------------------------------------------

Detailed SNP data, including the position, allele, and minor allele frequency, are presented in [Table 2](#pone.0232174.t002){ref-type="table"}. Two SNPs, rs1518111 and rs3021094, were not found to be in HWE in the control participants (*p* \< 0.05). Therefore, these two SNPs were excluded from subsequent statistical analyses. We assumed the minor allele of SNPs as the risk allele to analyze the correlation with breast cancer susceptibility. Our results show that polymorphisms of all candidate SNPs were not associated with breast cancer risk (*p* \> 0.05).

10.1371/journal.pone.0232174.t002

###### Allele frequencies in cases and controls and odds ratio estimates for breast cancer.

![](pone.0232174.t002){#pone.0232174.t002g}

  SNP ID      Band     Position    Role                Alleles A/B   MAF     *p*-HWE   OR(95%CI)                                      [^a^](#t002fn003){ref-type="table-fn"}*p*-value   
  ----------- -------- ----------- ------------------- ------------- ------- --------- ---------------------------------------------- ------------------------------------------------- -------
  rs1554286   1q32.1   206944233   Intron (boundary)   G/A           0.358   0.344     0.168                                          1.07(0.84--1.36)                                  0.605
  rs1518111   1q32.1   206944645   Intron (boundary)   C/T           0.358   0.338     0.043[^\#^](#t002fn002){ref-type="table-fn"}   1.1(0.86--1.4)                                    0.456
  rs3021094   1q32.1   206944952   Intron              G/T           0.436   0.447     0.022[^\#^](#t002fn002){ref-type="table-fn"}   0.95(0.76--1.2)                                   0.692
  rs3790622   1q32.1   206945163   Intron              A/G           0.081   0.08      0.429                                          1.02(0.67--1.57)                                  0.910
  rs3024490   1q32.1   206945311   Intron              C/A           0.355   0.334     0.099                                          1.09(0.86--1.4)                                   0.468
  rs1800871   1q32.1   206946634   Promoter            G/A           0.355   0.334     0.099                                          1.09(0.86--1.4)                                   0.468

SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; ORs, odds ratios; CI, confidence interval; A, minor allele; B, major allele.

^\#^Sites with HWE, *p* \< 0.05, are excluded.

^a^*p*-values were calculated using Pearson's Chi-square test.

Results from the genotype models are shown in [Table 3](#pone.0232174.t003){ref-type="table"}. Rs1554286 was associated with an increased risk of breast cancer in the co-dominant model (OR = 1.52, 95% CI = 1.07--2.16, *p* = 0.018). After adjusting for age, the OR was 1.51 (95% CI = 1.07--2.15, *p* = 0.018). Rs3024490 was also associated with an increased risk of breast cancer in the co-dominant model (OR = 1.65, 95% CI = 1.16--2.33, *p* = 0.004) and dominant model (OR = 1.43, 95% CI = 1.03--2.00, *p* = 0.033). After adjusting for age, significant associations were found in the co-dominant model (OR = 1.64, 95% CI = 1.16--2.33, *p* = 0.004) and dominant model (OR = 1.43, 95% CI = 1.02--2.00, *p* = 0.035). In addition, the co-dominant model (OR = 1.64, 95% CI = 1.16--2.33, *p* = 0.004) and dominant model (OR = 1.43, 95% CI = 1.02--2.00, *p* = 0.035) showed associations between rs1800871 and an increased risk of breast cancer in multiple comparisons adjusting for age. No significant associations were found for rs3790622.

10.1371/journal.pone.0232174.t003

###### Association between dominant single nucleotide polymorphisms (SNPs) and the risk of breast cancer in multiple inheritance models (adjusted by age).

![](pone.0232174.t003){#pone.0232174.t003g}

  SNP_ID      Model          Genotype   Genotype Frequencies   Without adjustment   With adjustment                                                                      
  ----------- -------------- ---------- ---------------------- -------------------- ------------------- -------------------------------------------- ------------------- --------------------------------------------
  rs1554286   Co-dominant    A/A        200 (37.7%)            282 (44.9%)          1                   0.018[\*](#t003fn004){ref-type="table-fn"}   1                   0.018[\*](#t003fn004){ref-type="table-fn"}
                             A/G        280 (52.8%)            260 (41.4%)          1.52 (1.07--2.16)                                                1.51 (1.07--2.15)   
                             G/G        50 (9.4%)              86 (13.7%)           0.82 (0.47--1.43)                                                0.82 (0.47--1.42)   
              Dominant       A/A        200 (37.7%)            282 (44.9%)          1                   0.081                                        1                   0.084
                             A/G-G/G    330 (62.3%)            346 (55.1%)          1.34 (0.96--1.88)                                                1.34 (0.96--1.87)   
              Recessive      A/A-A/G    480 (90.6%)            542 (86.3%)          1                   0.11                                         1                   0.11
                             G/G        50 (9.4%)              86 (13.7%)           0.66 (0.39--1.11)                                                0.65 (0.39--1.10)   
              Log-additive   \-\--      \-\--                  \-\--                1.07 (0.84--1.36)   0.6                                          1.07 (0.83--1.36)   0.62
  rs3790622   Co-dominant    G/G        444 (84.1%)            267 (85%)            1                   0.62                                         1                   0.62
                             A/G        82 (15.5%)             88 (14%)             1.12 (0.71--1.78)                                                1.12 (0.71--1.78)   
                             A/A        2 (0.4%)               6 (1%)               0.40 (0.04--3.88)                                                0.40 (0.04--3.90)   
              Dominant       G/G        444 (84.1%)            534 (85%)            1                   0.76                                         1                   0.75
                             A/G-A/A    84 (15.9%)             94 (15%)             1.07 (0.68--1.69)                                                1.08 (0.68--1.69)   
              Recessive      G/G-A/G    526 (99.6%)            622 (99%)            1                   0.39                                         1                   0.39
                             A/A        2 (0.4%)               6 (1%)               0.39 (0.04--3.81)                                                0.40 (0.04--3.83)   
              Log-additive   \-\--      \-\--                  \-\--                1.02 (0.67--1.57)   0.91                                         1.03 (0.67--1.57)   0.91
  rs3024490   Co-dominant    A/A        200 (37.7%)            292 (46.5%)          1                   0.004[\*](#t003fn004){ref-type="table-fn"}   1                   0.004[\*](#t003fn004){ref-type="table-fn"}
                             A/C        284 (53.6%)            252 (40.1%)          1.65 (1.16--2.33)                                                1.64 (1.16--2.33)   
                             C/C        46 (8.7%)              84 (13.4%)           0.80 (0.45--1.41)                                                0.80 (0.45--1.41)   
              Dominant       A/A        200 (37.7%)            292 (46.5%)          1                   0.033[\*](#t003fn004){ref-type="table-fn"}   1                   0.035[\*](#t003fn004){ref-type="table-fn"}
                             A/C-C/C    330 (62.3%)            336 (53.5%)          1.43 (1.03--2.00)                                                1.43 (1.02--2.00)   
              Recessive      A/A-A/C    484 (91.3%)            544 (86.6%)          1                   0.072                                        1                   0.071
                             C/C        46 (8.7%)              84 (13.4%)           0.62 (0.36--1.05)                                                0.61 (0.36--1.05)   
              Log-additive   \-\--      \-\--                  \-\--                1.10 (0.86--1.40)   0.46                                         1.09 (0.86--1.40)   0.47
  rs1800871   Co-dominant    A/A        200 (37.7%)            292 (46.5%)          1                   0.004[\*](#t003fn004){ref-type="table-fn"}   1                   0.004[\*](#t003fn004){ref-type="table-fn"}
                             A/G        284 (53.6%)            252 (40.1%)          1.65 (1.16--2.33)                                                1.64 (1.16--2.33)   
                             G/G        46 (8.7%)              84 (13.4%)           0.80 (0.45--1.41)                                                0.80 (0.45--1.41)   
              Dominant       A/A        200 (37.7%)            292 (46.5%)          1                   0.033[\*](#t003fn004){ref-type="table-fn"}   1                   0.035[\*](#t003fn004){ref-type="table-fn"}
                             A/G-G/G    330 (62.3%)            336 (53.5%)          1.43 (1.03--2.00)                                                1.43 (1.02--2.00)   
              Recessive      A/A-A/G    484 (91.3%)            544 (86.6%)          1                   0.072                                        1                   0.071
                             G/G        46 (8.7%)              84 (13.4%)           0.62 (0.36--1.05)                                                0.61 (0.36--1.05)   
              Log-additive   \-\--      \-\--                  \-\--                1.10 (0.86--1.40)   0.46                                         1.09 (0.86--1.40)   0.47

SNP, single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval.

^a^*p*-values were calculated using unconditional logistic regression analysis.

^b^*p*-values were calculated using unconditional logistic regression analysis with adjustments for age.

\**p* ≤ 0.05 indicates statistical significance.

Association between haplotypes and breast cancer risk {#sec015}
-----------------------------------------------------

Finally, LD analysis was used to assess the association between haplotypes and breast cancer susceptibility. Four SNPs (rs1554286, rs3790622, rs3024490 and rs1800871) had a strong LD, and the D' value was 1. This indicated that these four SNPs tended to be co-inherited ([Fig 1](#pone.0232174.g001){ref-type="fig"}). Furthermore, the haplotypes were not significantly associated with breast cancer susceptibility ([Table 4](#pone.0232174.t004){ref-type="table"}).

![Haplotype block map for part of the (SNPs) in the IL-10 gene.\
Four SNPs in the haplotype map (rs1554285, rs3790622, rs3024490, and rs1800871) had linkage disequilibrium (LD). A standard color frame is used to show the LD pattern. The D value was 1. These four SNPs tended to be co-inherited.](pone.0232174.g001){#pone.0232174.g001}

10.1371/journal.pone.0232174.t004

###### *IL-10* haplotype frequencies and the association with breast cancer risk.
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  Haplotype   rs1554286   rs3790622   rs3024490   rs1800871   Freq-case   Freq-control   Without adjustment   With adjustment                       
  ----------- ----------- ----------- ----------- ----------- ----------- -------------- -------------------- ----------------- ------------------- ------
  1           A           G           A           A           0.560       0.576          1                    \-                1                   \-
  2           G           G           C           G           0.355       0.334          1.10 (0.85--1.42)    0.48              1.09 (0.85--1.41)   0.49
  3           A           A           A           A           0.082       0.080          1.06 (0.68--1.64)    0.80              1.06 (0.68--1.64)   0.80
  rare        \*          \*          \*          \*          0.003       0.010          0.48 (0.11--2.15)    0.34              0.47 (0.11--2.13)   0.33

Freq, frequency; ORs, odds ratios; CI, confidence interval.

^a^*p*-values were calculated using unconditional logistic regression analysis without adjustment.

^b^*p*-values were calculated using unconditional logistic regression analysis with an adjustment for age.

Functional assessment of breast cancer-associated SNPs on IL-10 expression {#sec016}
--------------------------------------------------------------------------

After the association study, the effects of rs1554286, rs3024490, and rs1800871 on *IL-10* expression were evaluated using the GTEx database ([Table 5](#pone.0232174.t005){ref-type="table"}). We found that these three SNPs variants significantly affected the expression of *IL-10* in whole blood. Furthermore, Regulome DB was used to annotate the possible functional effect. Rs1554286 likely affected eQTL + TF binding / DNase peak and had a Regulome DB score of 1f, which is classified as "Likely to affect binding and linked to expression of a gene target". Rs3024490 had a Regulome DB score of 6, which is classified as "minimal binding evidence". In addition, rs1800871 was likely to affect TF binding + any motif + DNase peak, and it had a Regulome DB score of 3a, which is classified as "less likely to affect binding".

10.1371/journal.pone.0232174.t005

###### Functional annotation results.
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  SNP         NES    *p*-value    Tissue         Regulome DB Score   Function
  ----------- ------ ------------ -------------- ------------------- --------------------------------------------------------------------
  rs1554286   0.30   2.2×10^−9^   Whole Blood    1f                  Likely to affect binding and linked to expression of a gene target
  rs3024490   0.25   6.7×10^−5^   Nerve-Tibial   6                   Minimal binding evidence
  rs3024490   0.28   4.5×10^−9^   Whole Blood                        
  rs1800871   0.25   7.3×10^−5^   Nerve-Tibial   3a                  Less likely to affect binding
  rs1800871   0.28   4.5×10^−9^   Whole Blood                        

NES, Normalized effect size; 1f, eQTL + TF binding / DNase peak; 3a, TF binding + any motif + DNase peak; 6, other.

Moreover, we used the HaploReg database to get three genetic variants tagged by the rs3024490 and rs1800871 with r^2^ ≥ 0.8. These three polymorphisms were located in *IL-10* or upstream of *IL-10*. Detailed data, including LD information and predicted function, on these variants are shown in [Table 6](#pone.0232174.t006){ref-type="table"}. These results indicated the functional importance of rs1554286, rs3024490, and rs1800871, which were associated with breast cancer.

10.1371/journal.pone.0232174.t006

###### Breast cancer-associated single nucleotide polymorphisms (SNPs) with variants with r^2^ \> 0.8.

![](pone.0232174.t006){#pone.0232174.t006g}

  SNP         Chr: Position[^a^](#t006fn002){ref-type="table-fn"}   LD (r^2^)   LD(D')   Allele[^b^](#t006fn003){ref-type="table-fn"}   Gene                 HaploReg
  ----------- ----------------------------------------------------- ----------- -------- ---------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  rs1518111   1: 206771300                                          0.91        1        C/T                                            *IL-10* (intron)     Promoter histone marks, Enhancer histone marks, DNAse, Proteins bound, Motifs changed, NHGRI/EBI GWAS hits, GRASP QTL hits, Selected eQTL hits
  rs1518110   1: 206771516                                          0.89        0.98     C/A                                            *IL-10* (intron)     Promoter histone marks, Enhancer histone marks, DNAse, Motifs changed, Selected eQTL hits
  rs3024490   1: 206771966                                          1           1        C/A                                            *IL-10* (intron)     Promoter histone marks, Enhancer histone marks, Motifs changed, GRASP QTL hits, Selected eQTL hits
  rs1800872   1: 206773062                                          0.99        1        G/T                                            *IL-10* (upstream)   Promoter histone marks, Enhancer histone marks, Proteins bound, Motifs changed, GRASP QTL hits, Selected eQTL hits
  rs1800871   1: 206773289                                          1           1        G/A                                            *IL-10* (upstream)   Promoter histone marks, Enhancer histone marks, DNAse, Motifs changed, NHGRI/EBI GWAS hits, Selected eQTL hits

SNP, single nucleotide polymorphism; LD, linkage disequilibrium; eQTL, quantitative trait loci; GWAS, Genome-wide association study.

^a^Based on NCBI build 37 of the human genome.

^b^Reference allele/effect allele.

Discussion and conclusions {#sec017}
==========================

It is known that the polymorphisms of *IL-10* may contribute to the risk of breast cancer. Therefore, we selected six polymorphic sites that were located in the intron or promoter of *IL-10* and investigated their association with breast cancer susceptibility in Shaanxi Han women in China. The results show that the rs1554286 variant was associated with an increased risk of breast cancer in the co-dominant model. Additionally, rs3024490 and rs1800871 were associated with an increased breast cancer risk in co-dominant and dominant models. *In silico* analysis of the SNPs revealed that rs1554286, rs3024490, and rs1800871 may play important roles in the occurrence and development of breast cancer via regulating the expression of the target gene, *IL-10*. Our findings suggest that polymorphisms of *IL-10* may influence the risk of breast cancer among a group of Northwest Chinese Han women.

IL-10 is an important cytokine in immunity and cancer \[[@pone.0232174.ref019]\]. It is generally speculated that IL-10 plays a role in inhibiting the initiation and development of tumors by activating natural killer cells and cytotoxic T lymphocytes. Surviving tumor cells express IL-10, thus allowing them to escape immune recognition by reducing the expression of MHC class II \[[@pone.0232174.ref020]--[@pone.0232174.ref023]\]. A large number of association studies have found that polymorphisms of *IL-10* are involved in the susceptibility to many diseases, such as Bechcet's disease \[[@pone.0232174.ref024]\], systemic lupus erythematosus \[[@pone.0232174.ref025]\], and ulcerative colitis \[[@pone.0232174.ref026]\]. Meanwhile, some studies have indicated that IL-10 plays a vital role in the progression, invasion, migration, and growth of breast cancer \[[@pone.0232174.ref027], [@pone.0232174.ref028]\]. These results indicated that polymorphisms of *IL-10* have an effect on the development of breast cancer. Further research is needed to elucidate the relationships among IL-10, tumorigenesis, and progression.

In our study, we found a correlation between the rs1554286, rs3024490, or rs1800871 and the risk of breast cancer in the Northwest Chinese Han women. Several studies have reported a relationship between *IL-10* polymorphisms and breast cancer susceptibility. Slattery et al. reported that allele "G" of rs1554286 and rs1800871 are associated with the risk of breast cancer among women with Native American ancestry \[[@pone.0232174.ref008]\]. However, a meta-analysis showed that the rs1800871 polymorphism had no relationship with breast cancer risk in Caucasians \[[@pone.0232174.ref029]\]. Our results were inconsistent with these findings. The rs1800871, which is located in the promoter, may alter the transcriptional regulation of miRNA on *IL-10*. Our functional prediction also suggested that these variants may influence the expression and transcription factor binding of *IL-10*.

No significant results were found for rs1518111, rs3021094, and rs3790622. A variant of rs1518111 has been suggested to correlate with the development of lymphedema following breast cancer treatment \[[@pone.0232174.ref030]\]. According to SNPInfo analysis, rs3021094 is likely to alter a putative transcription factor binding site for the transcription of *IL-10* \[[@pone.0232174.ref031]\], and this SNP was significantly associated with poorer overall survival in patients with colorectal cancer \[[@pone.0232174.ref032]\]. The haplotype "GACC" formed by rs1518111, rs3021094, rs3790622, and rs1800871 was significantly related to the risk of Bechet's disease \[[@pone.0232174.ref033]\]. However, to date, there is limited information on the association of these three SNPs and the risk of breast cancer. Future studies are needed to confirm our findings in a larger sample size.

Although our study was powered adequately, there were several limitations. First, our study focused on Chinese Han women who lived in Shaanxi province. Second, although we identified significant associations between six SNPs in *IL-10* and breast cancer susceptibility, the mechanisms responsible for these associations remain unclear. In the future, we will want to explore the specific factors which connect the SNPs and the occurrence and development of breast cancer, containing transcriptional regulator and signal pathway.

Overall, this study provided a valuable argument that *IL-10* may be a risk factor for the development and progression of breast cancer. Future studies should replicate these findings and involve women from other regions.

Supporting information {#sec018}
======================
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Dear editors and reviewers:

On behalf of my co-authors, we thank you very much for giving us an opportunity to revise our manuscript, we appreciate you and reviewers very much for your positive and constructive comments on our manuscript entitled "Interleukin-10 polymorphisms are risk factors for breast cancer susceptibility and functional annotation " (ID: PONE-D-19-31344 R1). Those comments are all valuable and helpful for revising and improving our paper, as well as the important guiding significance to our researcher. We have studied comments carefully and have made correction which we hope meet with approval. We hope meet with approval.

We have carefully evaluated the reviewers' critical comments and thoughtful suggestions, responded to these suggestions point-by-point, and revised the manuscript. Revised portion are marked using the track changes mode in the marked manuscript.

The main corrections in the paper and the responds to the reviewer's comments are as follows:

Response to Journal Requirements:

1.When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: We thank the editor\'s for scrutinize. We revised the manuscript according to the reviewer\'s suggestion. Thank you again for your careful review of our manuscript.

2.In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a description of how participants were recruited, and d) descriptions of where participants were recruited.

Response: We thank the editor\'s for scrutinize. We have revised this issue in the manuscript according to the reviewer\'s suggestion (line 92-102, page 15). Thank you again for your careful review of our manuscript.

3\. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

Response: We thank the editor\'s for scrutinize. We have revised this issue in the manuscript according to the reviewer\'s suggestion (line 83-90, page 5). Thank you again for your careful review of our manuscript.

Responds to the reviewer's comments:

Response to Reviewer \#1:

Major Concerns:

1)In the third line of page 12 you talk about the rs 1800871, as a mutation. It is a mistake.

Response: We thank the reviewer's for scrutinize. I am sorry for this type of writing error in our manuscript. And we have revised such mistakes in the manuscript according to the reviewer\'s suggestion (line 3, page 12). Thank you again for your careful review of our manuscript.

2\) You haven't calculated if there are statistically significant differences between cases and controls for menopausal state.

Response: We thank the reviewer's for scrutinize. The menopause information of the case group in this study is comprehensive, while the menopause-related information of the healthy control group is not comprehensive, so we have not calculated whether there is a statistically significant difference between the menopausal case and the control group. When we conduct further in-depth research in the future, we will collect the clinical information of the subjects as much as possible, and conduct a more comprehensive and in-depth experimental design. Thank you again for your careful review of our manuscript.

Response to Reviewer \#2:

1.The clinical validity of the OR depends on how the control group is representative of the entire population and how influent are all the other factors present in the cases, which could independently give an association with the disease. Given the lack of representativeness of the sample, as it relates only to the province of Shaanxi, it could be useful to report the values of likelihood ratio which take into account the epidemiological data of this specific province. This allows to be clearer about the risk of bias due to a stratification of the population;

Response: We thank the reviewer's for scrutinize. The cases and control population in this study were both Han populations from Shaanxi Province. We revised the writing in the manuscript based on the reviewer\'s suggestion. Thank you again for your careful review of our manuscript.

2.In order to support the hypothesis, that the presence of polymorphisms affects the expression of IL-10, it would be appropriate to report data that support the formulation of this hypothesis (e.g. variation of IL-10 transcripts in the presence of a particular allele or haplotype), taking in account that the haplotypes analyzed do not show a significant association with breast cancer, as reported by the same authors;

Response: We thank the reviewer's for scrutinize. At present, many studies have reported that changes in SNPs loci can affect the expression of regulatory genes in a variety of ways (1. Cibele Masotti, Lucia M. Armelin-Correa, Alessandra Splendore,等. A functional SNP in the promoter region of TCOF1 is associated with reduced gene expression and YY1 DNA--protein interaction\[J\]. 359(none):0-52. 2. Yuan L, Shen S, Luo C. SNP Identification in α\_(2A)-Adrenergic Receptor Gene in Chinese and the Effect on Gene Expression\[J\]. 2003, 17(6):277-282. 3.Safaa I. Tayel, Eman A. M. Fouda, Elsayed I. Elshayeb,ect. Biochemical and molecular study on interleukin‐1β gene expression and relation of single nucleotide polymorphism in promoter region with Type 2 diabetes mellitus\[J\]. Journal of Cellular Biochemistry, 2018, 119(7)).

In this study, we referenced reference "Xu Z , Taylor J A . SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies\[J\]. Nucleic Acids Research, 2009, 37(Web Server):W600-W605", and initially annotated the functions of selected SNPs through the GTEx database and the HaploReg database. The prediction results showed that these sites have different regulatory functions ((line 189-205, page 10). However, further research is needed to further explore how the candidate SNPs affect IL-10 expression. We will further collect samples to explore this issue later. Thank you again for your careful review of our manuscript.

3.When so few SNPs are genotyped, it is difficult to establish the failure rate and heterozygosity rate for markers quality control procedures. It is however advisable to remove individuals with low call rates. This article does is not explicit on the call rate of individuals, neither on the threshold at which individuals are excluded, or whether individuals have been excluded. We believe that these data should be highlighted because they define the reproducibility of the experiment. There are also no references about the presence of any familiar relationship between the selected individuals, which might be source of bias in a population-based case-control study, given that the enrollment is limited within a specific province;

Response: We thank the reviewers for their review. We modified the manuscript based on the reviewer\'s recommendations (page 111-116, line 6; page 127, line 7; page 102, line 6). Thank you again for your careful review of our manuscript.

4.The authors speculated that the lower frequency allele could be associated with the disease. However, in table 2, when the frequencies of the minor allele are compared in the two groups of cases and controls, we notice that there is no significant difference (p-values \> 0.05) as reported same authors within the text; we suggest reporting the reasons that led the authors to consider the minor allele as the one associated with the disease and also the allelic frequencies of the major allele;

Response: We thank the reviewer's for scrutinize. As shown in Table 2, We hypothesized that the minor allele of the SNP was the risk allele to analyze the correlation with breast cancer susceptibility. Our results show that under this allele model, the minor alleles of all candidate SNPs have no significant correlation with breast cancer risk (p\> 0.05).

However, the genetic loci in nature exist in the form of genotypes. We further analyzed the relationship between the corresponding genotypes and the risk of breast cancer under different genetic models in Table 3.

5.We suggest the authors to provide more clarifications on the selection criteria of the 6 starting SNPs of the study;

Response: We thank the reviewer's for scrutinize. In this study, six SNPs (rs1554286, rs1518111, rs3021094, rs3790622, rs3024490, rs1800871) of IL-10 were selected from the DbSNP (<http://www.hapmap.org/index.html.en>) and SNP Consortium (<http://snp.cshl.org/>) databases based on the following criteria. We took allele frequency into consideration during genotyping. The lower frequency alleles were coded as minor alleles. All SNPs were selected at a minor allele frequency \>5% in 1,000 genome project (<http://www.internationalgenome.org/>). In addition, the genotype distribution of SNPs in the control group was in accordance with Hardy-weinberg equilibrium (HWE) (p \> 0.05). The genotyping of Agena MassARRAY RS1000 for these SNPs exceeded 95.0%. The Haploview software package (version 4.2) was used to estimate the pairwise linkage disequilibrium (LD) of the IL-10 polymorphic site. When r2 (measured value of LD) \> 0.8, SNP can represent all polymorphisms in a block (page 118-127, line 7).

6.For the benefit of the reader, it could be useful to specify the criteria on the basis of which an \"age correction\" of the subjects in the study was made;

Response: We thank the reviewer's for scrutinize. As shown in Table 1, the average age of cases and controls was 50.69 years and 51.04 years, respectively. Welch\'s t-test showed a significant difference in age between the cases and the controls (p = 0.001). In order to exclude the effects of age differences and confounding factors in subsequent statistics, we adjusted the age.

7.Table 3 is not clear in the graphic construction and difficult to read, especially the column related to the genotypes referred to each model (describe all the genotypes in comparison for each model) and in the section related to the p-value (review text alignment and report all p-values);

Response: We thank the reviewer's for scrutinize. For a single nucleotide polymorphism, we hypothesized that the minor allele of each SNP was a risk factor compared with the wild-type allele. In this case-control study, we referred to a published article entitled "Basic statistical analysis in genetic case-control studies" about statistical analysis (Clarke G M, Anderson C A, Pettersson F H, et al. Basic statistical analysis in genetic case-control studies \[J\]. Nature Protocol, 2011, 6(2):121-133). In this paper, the author showed that the disease risk is really the cumulative effect of the risk alleles.

When we consider a genetic marker consisting of a single bi-allelic locus with alleles a and A (i.e., a SNP), three possible genotypes are G/G, G/A and A/A (A is the minor allele). Multiple genetic models are shown as follows: allelic model: G vs A; dominant model: AA+AG vs GG; recessive model: AA vs AG+GG; codominant model: AA vs AG vs GG; the log-additive model indicates that the risk of disease is increased 1-fold for genotype a/A and by 2-fold for genotype A/A. The corresponding P values correspond to different models.

For example, in Table 3, rs1554286, Co-dominant refers to G / G vs A / G vs A / A, and the corresponding p-values before and after correction are 0.018 \* and 0.018 \*, respectively; Dominant model refers to A / G-G / G vs A / A, and the corresponding p-values are 0.081 and 0.084 before and after correction, respectively; Recessive model refers to G / G vs A / A-A / G, and the corresponding p-values before and after correction are 0.11 and 0.11, respectively; the corresponding p-values before and after correction in the Log-additive model are 0.60 and 0.62, respectively. We modified the Table 3 based on the reviewer\'s recommendations. Thank you again for your careful review of our manuscript.

8.At first glance, the title seems to make a statement that is not sufficiently proven by the results drawn in the article, if not by hypothetical models which, however, are not sufficiently validated. We therefore consider premature to state that \"IL-10 polymorphisms ARE risk factors for breast cancer susceptibility\". It would be advisable to make a revision of the title according to the hypothetical value of the results;

Response: We thank the reviewer's for scrutinize. We modified the manuscript based on the reviewer\'s recommendations (page 1, line 1). Thank you again for your careful review of our manuscript.

9.Finally, we advise the authors to avoid elements of repetitiveness in the discussion, in order to make reading more smooth and pleasant.

Response: We thank the reviewer's for scrutinize. We modified the manuscript based on the reviewer\'s recommendations (page 226, line 12). Thank you again for your careful review of our manuscript.

We appreciate for Editors/Reviewers' warm work earnestly, the reviewer's comments are quite helpful. We revised our paper point-by-point problems. Finally, we hope that the correction will meet with approval. Looking forward to hearing from you.

Thank you and best regards!
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